Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Mirati and Verastem Combine to Address Unmet Need in KRAS G12C–Mutant NSCLC

January 5th 2022

Mirati Therapeutics and Verastem Oncology have entered a nonexclusive clinical collaboration to evaluate the combination of adagrasib plus VS-6766 for patients with non–small cell lung cancer harboring a KRAS G12C mutation who have progressed on a KRAS G12C inhibitor in a phase 1/2 trial.

Telisotuzumab Vedotin Receives Breakthrough Therapy Status From FDA for Select NSCLC

January 5th 2022

The FDA granted a breakthrough therapy designation to telisotuzumab vedotin for use in patients with advanced or metastatic EGFR wild-type, nonsquamous non–small cell lung cancer who have high levels of c-Met overexpression and whose disease has progressed on, or after, platinum-based chemotherapy.

Predominant Lung Cancer Investigator Welcomes a New Era of Research

January 5th 2022

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC

January 4th 2022

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

CLN-081 Granted FDA Breakthrough Therapy Designation Status for EGFR-Mutated NSCLC

January 4th 2022

The FDA has granted breakthrough therapy designation to CLN-081 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy.

How Has Biomarker Testing Impacted Clinical Practice Across Geographic Regions?

January 4th 2022

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

Treatment Options for LEMS

January 4th 2022

Key opinion leaders detail the treatment options available for Lambert-Eaton myasthenic syndrome.

Front-line Treatment Options for SCLC

January 4th 2022

Steven Vernino, MD, describes the first-line treatment options for small cell lung cancer with Lambert-Eaton myasthenic syndrome.

FDA Grants Fast Track Status to Novel Gene Therapy Plus Pembrolizumab for Late-Stage NSCLC

January 3rd 2022

The FDA has granted a fast track designation to a combination comprised of the immunogene therapy quaratusugene ozeplasmia and pembrolizumab for use in select patients with late-stage non–small cell lung cancer.

Available Treatment Options for Patients With EGFR Mutant NSCLC

January 3rd 2022

Tony SK Mok, MD, and Solange Peters, MD, PhD, relay the available treatment options for EGFR mutant NSCLC—both early and advanced stages.

ADAURA and Selecting Adjuvant Therapy in EGFR Mutant Early-Stage NSCLC

January 3rd 2022

Dr Mok finishes our discussion on the ADAURA trial, and Dr Peters delves into selecting the right adjuvant therapy for a patient with early-stage EGFR mutant NSCLC.

Biomarkers Light the Way for Personalized Treatment in NSCLC

December 30th 2021

Jyoti D. Patel, MD, discusses biomarker testing, interpreting molecular result reports, and the growing armamentarium for patients with oncogene-driven lung cancer.

Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade

December 30th 2021

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

Shifting Regulatory Approval Pathway Is a Top Takeaway of 2021 in Lung Cancer

December 29th 2021

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.

LEMS Case Review

December 28th 2021

Drs. David Gerber and Steven Vernino review the case of a 64-year-old man with Lambert-Eaton myasthenic syndrome.

LEMS Diagnosis: Patient Presentation and Testing

December 28th 2021

Two experts debate the preferred testing options for Lambert-Eaton myasthenic syndrome presenting with small cell lung cancer.

Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC

December 23rd 2021

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

December 23rd 2021

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for EGFR+ NSCLC

December 23rd 2021

The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non–small cell lung cancer with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.

Dr. Gold on Leveraging Sotorasib in KRAS G12C–Mutated NSCLC

December 22nd 2021

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.